Ursodeoxycholic acid relieves clinical severity of COVID-19 in patients with chronic liver diseases
BackgroundThe potential effect of ursodeoxycholic acid (UDCA) on the clinical outcomes of SARS-CoV-2 in patients with chronic liver diseases has been a subject of ongoing debate since the onset of the SARS-CoV-2 pandemic in 2019. This study aims to investigate the effect of UDCA on the prognosis of...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1494248/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832087095344103424 |
|---|---|
| author | Tiantian Hu Tiantian Hu Jie Tong Yunhui Yang Changrong Yuan Jiming Zhang Jiming Zhang Jiming Zhang Jinyu Wang Jinyu Wang |
| author_facet | Tiantian Hu Tiantian Hu Jie Tong Yunhui Yang Changrong Yuan Jiming Zhang Jiming Zhang Jiming Zhang Jinyu Wang Jinyu Wang |
| author_sort | Tiantian Hu |
| collection | DOAJ |
| description | BackgroundThe potential effect of ursodeoxycholic acid (UDCA) on the clinical outcomes of SARS-CoV-2 in patients with chronic liver diseases has been a subject of ongoing debate since the onset of the SARS-CoV-2 pandemic in 2019. This study aims to investigate the effect of UDCA on the prognosis of SARS-CoV-2 infection in patients with chronic liver diseases.MethodsA total of 926 patients with chronic liver diseases who contracted their first SARS-CoV-2 infection during December 2022 to January 2023, were included in this study. Participants were divided into two groups based on the use of UDCA: the UDCA cohort (n = 329) and the non-UDCA cohort (n = 597). After performing a 1:1 age-and sex-matching, the analysis proceeded with 309 patients from each group for further evaluation.ResultsIn the UDCA-treated cohort, the incidence of asymptomatic SARS-CoV-2 infections was significantly higher, with 30.1% of patients affected, compared to 6.47% in the non-UDCA group (p < 0.0001). Multivariable analysis identified UDCA as a protective factor against symptomatic infections, yielding an odds ratio (OR) of 4.77 (95% CI: 2.70–8.44, p < 0.001). Furthermore, age over 50 was found to be a risk factor for asymptomatic infections in the UDCA cohort, with an adjusted OR of 1.51 (95% CI: 1.01–2.24, p = 0.05).ConclusionThe study suggests that UDCA therapy may improve clinical outcomes in patients with chronic liver diseases patients who are infected with SARS-CoV-2, highlighting its potential role in improving prognosis within this vulnerable population. However, further research is required to validate these findings and to elucidate the mechanisms underlying UDCA’s protective effect. |
| format | Article |
| id | doaj-art-1981c8419cf94330bcd429d5a9ea73d6 |
| institution | Kabale University |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-1981c8419cf94330bcd429d5a9ea73d62025-02-06T07:10:24ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-02-011210.3389/fmed.2025.14942481494248Ursodeoxycholic acid relieves clinical severity of COVID-19 in patients with chronic liver diseasesTiantian Hu0Tiantian Hu1Jie Tong2Yunhui Yang3Changrong Yuan4Jiming Zhang5Jiming Zhang6Jiming Zhang7Jinyu Wang8Jinyu Wang9Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, ChinaFudan University School of Nursing, Fudan University, Shanghai, ChinaDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, ChinaDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, ChinaFudan University School of Nursing, Fudan University, Shanghai, ChinaDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, ChinaShanghai Institute of Infectious Diseases and Biosecurity, Key Laboratory of Medical Molecular Virology (MOE/MOH), Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Infectious Diseases, Jing’An Branch of Huashan Hospital, Fudan University, Shanghai, ChinaDepartment of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, ChinaShanghai Institute of Infectious Diseases and Biosecurity, Key Laboratory of Medical Molecular Virology (MOE/MOH), Shanghai Medical College, Fudan University, Shanghai, ChinaBackgroundThe potential effect of ursodeoxycholic acid (UDCA) on the clinical outcomes of SARS-CoV-2 in patients with chronic liver diseases has been a subject of ongoing debate since the onset of the SARS-CoV-2 pandemic in 2019. This study aims to investigate the effect of UDCA on the prognosis of SARS-CoV-2 infection in patients with chronic liver diseases.MethodsA total of 926 patients with chronic liver diseases who contracted their first SARS-CoV-2 infection during December 2022 to January 2023, were included in this study. Participants were divided into two groups based on the use of UDCA: the UDCA cohort (n = 329) and the non-UDCA cohort (n = 597). After performing a 1:1 age-and sex-matching, the analysis proceeded with 309 patients from each group for further evaluation.ResultsIn the UDCA-treated cohort, the incidence of asymptomatic SARS-CoV-2 infections was significantly higher, with 30.1% of patients affected, compared to 6.47% in the non-UDCA group (p < 0.0001). Multivariable analysis identified UDCA as a protective factor against symptomatic infections, yielding an odds ratio (OR) of 4.77 (95% CI: 2.70–8.44, p < 0.001). Furthermore, age over 50 was found to be a risk factor for asymptomatic infections in the UDCA cohort, with an adjusted OR of 1.51 (95% CI: 1.01–2.24, p = 0.05).ConclusionThe study suggests that UDCA therapy may improve clinical outcomes in patients with chronic liver diseases patients who are infected with SARS-CoV-2, highlighting its potential role in improving prognosis within this vulnerable population. However, further research is required to validate these findings and to elucidate the mechanisms underlying UDCA’s protective effect.https://www.frontiersin.org/articles/10.3389/fmed.2025.1494248/fullchronic liver diseasesSARS-CoV-2ursodeoxycholic acidprognosisclinical outcomes |
| spellingShingle | Tiantian Hu Tiantian Hu Jie Tong Yunhui Yang Changrong Yuan Jiming Zhang Jiming Zhang Jiming Zhang Jinyu Wang Jinyu Wang Ursodeoxycholic acid relieves clinical severity of COVID-19 in patients with chronic liver diseases Frontiers in Medicine chronic liver diseases SARS-CoV-2 ursodeoxycholic acid prognosis clinical outcomes |
| title | Ursodeoxycholic acid relieves clinical severity of COVID-19 in patients with chronic liver diseases |
| title_full | Ursodeoxycholic acid relieves clinical severity of COVID-19 in patients with chronic liver diseases |
| title_fullStr | Ursodeoxycholic acid relieves clinical severity of COVID-19 in patients with chronic liver diseases |
| title_full_unstemmed | Ursodeoxycholic acid relieves clinical severity of COVID-19 in patients with chronic liver diseases |
| title_short | Ursodeoxycholic acid relieves clinical severity of COVID-19 in patients with chronic liver diseases |
| title_sort | ursodeoxycholic acid relieves clinical severity of covid 19 in patients with chronic liver diseases |
| topic | chronic liver diseases SARS-CoV-2 ursodeoxycholic acid prognosis clinical outcomes |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2025.1494248/full |
| work_keys_str_mv | AT tiantianhu ursodeoxycholicacidrelievesclinicalseverityofcovid19inpatientswithchronicliverdiseases AT tiantianhu ursodeoxycholicacidrelievesclinicalseverityofcovid19inpatientswithchronicliverdiseases AT jietong ursodeoxycholicacidrelievesclinicalseverityofcovid19inpatientswithchronicliverdiseases AT yunhuiyang ursodeoxycholicacidrelievesclinicalseverityofcovid19inpatientswithchronicliverdiseases AT changrongyuan ursodeoxycholicacidrelievesclinicalseverityofcovid19inpatientswithchronicliverdiseases AT jimingzhang ursodeoxycholicacidrelievesclinicalseverityofcovid19inpatientswithchronicliverdiseases AT jimingzhang ursodeoxycholicacidrelievesclinicalseverityofcovid19inpatientswithchronicliverdiseases AT jimingzhang ursodeoxycholicacidrelievesclinicalseverityofcovid19inpatientswithchronicliverdiseases AT jinyuwang ursodeoxycholicacidrelievesclinicalseverityofcovid19inpatientswithchronicliverdiseases AT jinyuwang ursodeoxycholicacidrelievesclinicalseverityofcovid19inpatientswithchronicliverdiseases |